| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
38,010,000 |
| Market
Cap: |
125.43(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.12 - $4.98 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 935 |
| Guru Rank Value : 0 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile G1 Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. Co.'s primary compound trilaciclib is a therapy designed to help protect against chemotherapy-induced myelosuppression. Trilaciclib helps protect hematopoietic stem and progenitor cells in the bone marrow by transiently inhibiting CDK4/6 leading to a temporary arrest of susceptible host cells during chemotherapy in patients. Rintodestrant is an oral selective estrogen receptor degrader for the treatment of ER+ breast cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
90,386 |
212,211 |
278,007 |
460,221 |
| Total Sell Value |
$418,207 |
$855,824 |
$990,019 |
$3,011,511 |
| Total People Sold |
7 |
7 |
8 |
10 |
| Total Sell Transactions |
8 |
21 |
26 |
43 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Malik Rajesh |
Ch. Medical Officer & SVP R&D |
• – – |
2018-10-15 |
4 |
AS |
$40.80 |
$157,497 |
D/D |
(3,776) |
8,400 |
|
- |
|
| Velleca Mark A. |
President and CEO |
• • – |
2018-10-15 |
4 |
AS |
$40.90 |
$207,645 |
D/D |
(5,000) |
19,000 |
|
- |
|
| Velleca Mark A. |
President and CEO |
• • – |
2018-10-15 |
4 |
OE |
$3.72 |
$18,600 |
D/D |
5,000 |
24,000 |
|
- |
|
| Velleca Mark A. |
President and CEO |
• • – |
2018-10-11 |
4 |
OE |
$0.39 |
$3,900 |
D/D |
10,000 |
19,000 |
|
- |
|
| Moses Jennifer K. |
VP of Finance & Admin |
• – – |
2018-10-08 |
4 |
AS |
$44.52 |
$33,390 |
D/D |
(750) |
2,000 |
|
- |
|
| Moses Jennifer K. |
VP of Finance & Admin |
• – – |
2018-10-08 |
4 |
OE |
$0.39 |
$293 |
D/D |
750 |
2,750 |
|
- |
|
| Strum Jay |
Chief Scientific Officer |
• – – |
2018-10-04 |
4 |
OE |
$0.30 |
$255 |
D/D |
850 |
49,419 |
|
- |
|
| Rudnick Seth |
|
– • – |
2018-10-04 |
4 |
AS |
$49.65 |
$497,210 |
D/D |
(10,000) |
0 |
|
- |
|
| Rudnick Seth |
|
– • – |
2018-10-04 |
4 |
OE |
$0.39 |
$3,900 |
D/D |
10,000 |
10,000 |
|
- |
|
| Murdock Terry L |
SVP of Development Operations |
• – – |
2018-10-03 |
4 |
AS |
$49.18 |
$173,064 |
D/D |
(3,519) |
0 |
|
- |
|
| Murdock Terry L |
SVP of Development Operations |
• – – |
2018-10-03 |
4 |
OE |
$13.51 |
$47,542 |
D/D |
3,519 |
3,519 |
|
- |
|
| Velleca Mark A. |
President and CEO |
• • – |
2018-09-17 |
4 |
AS |
$65.74 |
$331,549 |
D/D |
(5,000) |
9,000 |
|
- |
|
| Velleca Mark A. |
President and CEO |
• • – |
2018-09-17 |
4 |
OE |
$3.72 |
$18,600 |
D/D |
5,000 |
14,000 |
|
- |
|
| Malik Rajesh |
Ch. Medical Officer & SVP R&D |
• – – |
2018-09-17 |
4 |
AS |
$65.78 |
$249,502 |
D/D |
(3,776) |
8,400 |
|
- |
|
| Malik Rajesh |
Ch. Medical Officer & SVP R&D |
• – – |
2018-09-17 |
4 |
OE |
$4.17 |
$15,746 |
D/D |
3,776 |
12,176 |
|
- |
|
| Moses Jennifer K. |
VP of Finance & Admin |
• – – |
2018-09-05 |
4 |
OE |
$0.39 |
$7,733 |
D/D |
2,750 |
2,000 |
|
- |
|
| Moses Jennifer K. |
VP of Finance & Admin |
• – – |
2018-09-05 |
4 |
AS |
$59.60 |
$44,700 |
D/D |
(750) |
0 |
|
- |
|
| Murdock Terry L |
SVP of Development Operations |
• – – |
2018-09-04 |
4 |
AS |
$59.98 |
$211,065 |
D/D |
(3,519) |
0 |
|
- |
|
| Murdock Terry L |
SVP of Development Operations |
• – – |
2018-09-04 |
4 |
OE |
$13.51 |
$47,542 |
D/D |
3,519 |
3,519 |
|
- |
|
| Rudnick Seth |
|
– • – |
2018-09-04 |
4 |
AS |
$59.93 |
$599,483 |
D/D |
(10,000) |
0 |
|
- |
|
| Rudnick Seth |
|
– • – |
2018-09-04 |
4 |
OE |
$0.39 |
$3,900 |
D/D |
10,000 |
10,000 |
|
- |
|
| Strum Jay |
Chief Scientific Officer |
• – – |
2018-08-30 |
4 |
S |
$59.27 |
$299,876 |
D/D |
(5,000) |
48,569 |
|
- |
|
| Strum Jay |
Chief Scientific Officer |
• – – |
2018-08-29 |
4 |
S |
$58.40 |
$296,095 |
D/D |
(5,000) |
53,569 |
|
- |
|
| Malik Rajesh |
Ch. Medical Officer & SVP R&D |
• – – |
2018-08-15 |
4 |
AS |
$55.38 |
$211,023 |
D/D |
(3,776) |
8,400 |
|
- |
|
| Malik Rajesh |
Ch. Medical Officer & SVP R&D |
• – – |
2018-08-15 |
4 |
OE |
$4.17 |
$15,746 |
D/D |
3,776 |
12,176 |
|
- |
|
335 Records found
|
|
Page 10 of 14 |
|
|
0.01 (0.3%) 
